Retroviral gene therapy: Safety issues and possible solutions

Current Gene Therapy

Volumn 5, Issue 1, 2005, Pages 25-35

  Yi, Youngsuk ^a   Hahm, Sung Ho ^b   Lee, Kwan Hee ^a,c  

^a TissueGene   (United States)

^b Omega Biosciences LLC   (United States)

^c Inha University School of Medicine   (South Korea)

Author keywords

Gene; Insertional; Insulator; Retroviral; Safety; Targeted; Therapy; Vectors

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; GANCICLOVIR; INTERLEUKIN 2; INTERLEUKIN RECEPTOR; POL PROTEIN; RETROVIRUS VECTOR; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA; VIRUS ENVELOPE PROTEIN;

ADVANCED CANCER; CANCER RISK; CARCINOGENESIS; CARTILAGE DEGENERATION; CELL DESTRUCTION; CELL GROWTH; CELL SPECIFICITY; CHROMATIN; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DRUG SAFETY; GENE ACTIVATION; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; LEUKEMIA; MELANOMA; NONHUMAN; PROMOTER REGION; PROTO ONCOGENE; REVIEW; SEQUENCE ANALYSIS; SUICIDE GENE THERAPY; TARGET CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INACTIVATION; X CHROMOSOME LINKED DISORDER;

EID: 13844254514     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/1566523052997514     Document Type: Review

References (114)

1. Agarwal, M., Austin, T. W., Morel, F., Chen, J., Bohnlein, E. and Plavec, I. (1998) Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J Virol. 72: 3720-8.
2. Anderson, W. F. (2000) Gene therapy. The best of times, the worst of times. Science. 288: 627-9.
3. Barzon, L., Bonaguro, R., Castagliuolo, I., Chilosi, M., Franchin, E., Del Vecchio, C., Giaretta, I., Boscaro, M. and Palu, G. (2003) Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur. J. Endocrinol., 148: 73-80.
4. Baum, C., Dullmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D. A. and von Kalle, C. (2003) Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 101: 2099-114.
5. Behrens, A., Gordon, E. M., Li, L., Liu, P. X., Chen, Z., Peng, H., La Bree, L., Anderson, W. F., Hall, F. L. and McDonnell, P. J. (2002) Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. Invest. Ophthalmol. Vis. Sci., 43 968-77.
6. Bienemann, A. S., Martin-Rendon, E., Cosgrave, A. S., Glover, C. P., Wong, L. F., Kingsman, S. M., Mitrophanous, K. A., Mazarakis, N. D. and Uney, J. B. (2003) Long-term replacement of a mutated nonfunctional CNS gene: reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin. Mol. Ther., 7: 588-96.
7. Bittner, A., Mitnacht-Kraus, R. and Schnierle, B. S. (2002) Specific transduction of HIV-1 envelope expressing cells by retroviral vectors pseudotyped with hybrid CD4/CXCR4 receptors. J. Virol. Methods 104: 83-92.
8. Bode, J., Benham, C., Knopp, A. and Mielke, C. (2000) Transcriptional augmentation: modulation of gene expression by scaffold/matrix-attached regions (S/MAR elements). Crit. Rev. Eukaryot. Gene Expr., 10: 73-90.
9. Bode, J., Kohwi, Y., Dickinson, L., Joh, T., Klehr, D., Mielke, C. and Kohwi-Shigematsu, T. (1992) Biological significance of unwinding capability of nuclear matrix-associating DNAs. Science, 255: 195-7.
10. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C. and Bordignon, C. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719-24.
11. Buchholz, C. J., Peng, K. W., Morling, F. J., Zhang, J., Cosset, F. L. and Russell, S. J. (1998) In vivo selection of protease cleavage sites from retrovirus display libraries. Nat. Biotechnol., 16: 951-4.
12. Burgess-Beusse, B., Farrell, C., Gaszner, M., Litt, M., Mutskov, V., Recillas-Targa, F., Simpson, M., West, A. and Felsenfeld, G. (2002) The insulation of genes from external enhancers and silencing chromatin. Proc. Natl. Acad. Sci. USA, 99 Suppl 4: 16433-7.
13. Burns, J. C., Friedmann, T., Driever, W., Burrascano, M. and Yee, J. K. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA, 90: 8033-7.
14. Bushman, F. D. and Miller, M. D. (1997) Tethering human immunodeficiency virus type 1 preintegration complexes to target DNA promotes integration at nearby sites. J. Virol., 71: 458-64.
15. Callahan, M. E., Switzer, W. M., Matthews, A. L., Roberts, B. D., Heneine, W., Folks, T. M. and Sandstrom, P. A. (1999) Persistent zoonotic infection of a human with simian foamy virus in the absence of an intact orf-2 accessory gene. J. Virol., 73: 9619-24.
16. Cao, G., Kuriyama, S., Gao, J., Nakatani, T., Chen, Q., Yoshiji, H., Zhao, L., Kojima, H., Dong, Y., Fukui, H. and Hou, J. (2001) Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter. Eur. J. Cancer, 37: 140-7.
17. Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J. L., Bousso, P., Deist, F. L. and Fischer, A. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 288: 669-72.
18. Chaudry, G. J., Farrell, K. B., Ting, Y. T., Schmitz, C., Lie, S. Y., Petropoulos, C. J. and Eiden, M. V. (1999) Gibbon ape leukemia virus receptor functions of type III phosphate transporters from CHOK1 cells are disrupted by two distinct mechanisms. J. Virol., 73: 2916-20.
19. Chen, R. (2001) Enzyme engineering: rational redesign versus directed evolution. Trends Biotechnol., 19: 13-4.
20. Chung, J. H., Bell, A. C. and Felsenfeld, G. (1997) Characterization of the chicken beta-globin insulator. Proc. Natl. Acad. Sci. USA, 94: 575-80.
21. Chung, J. H., Whiteley, M. and Felsenfeld, G. (1993) A 5′ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell, 74: 505-14.
22. Connolly, J. B. (2002) Lentiviruses in gene therapy clinical research. Gene Ther., 9: 1730-4.
23. Cosset, F. L., Morling, F. J., Takeuchi, Y., Weiss, R. A., Collins, M. K. and Russell, S. J. (1995) Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol., 69 6314-22.
24. Di Simone, P., Di Leonardo, A., Costanzo, G., Melfi, R. and Spinelli, G. (2001) The sea urchin sns insulator blocks CMV enhancer following integration in human cells. Biochem. Biophys. Res. Commun. 284: 987-92.
25. Drobyski, W. R., Gendelman, M., Vodanovic-Jankovic, S. and Gorski, J. (2003) Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation. J. Immunol., 170: 3046-53.
26. Emery, D. W., Yannaki, E., Tubb, J., Nishino, T., Li, Q. and Stamatoyannopoulos, G. (2002) Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood, 100: 2012-9.
27. Emery, D. W., Yannaki, E., Tubb, J. and Stamatoyannopoulos, G. (2000) A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc. Natl. Acad. Sci. USA, 97: 9150-5.
28. Engelstadter, M., Bobkova, M., Baier, M., Stitz, J., Holtkamp, N., Chu, T. H., Kurth, R., Dornburg, R., Buchholz, C. J. and Cichutek, K. (2000) Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library. Hum. Gene Ther., 11: 293-303.
29. Evans, C. H., Ghivizzani, S. C., Herndon, J. H., Wasko, M. C., Reinecke, J., Wehling, P. and Robbins, P. D. (2000) Clinical trials in the gene therapy of arthritis. Clin. Orthop., S300-7.
30. Evans, C. H. and Scully, S. P. (2000) Orthopaedic gene therapy. Clin Orthop. S2.
31. Farson, D., Witt, R., McGuinness, R., Dull, T., Kelly, M., Song, J., Radeke, R., Bukovsky, A., Consiglio, A. and Naldini, L. (2001) A new-generation stable inducible packaging cell line for lentiviral vectors. Hum. Gene Ther., 12: 981-97.
32. Ferrari, G., Salvatori, G., Rossi, C., Cossu, G. and Mavilio, F. (1995) A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum. Gene Ther., 6: 733-42.
33. Fielding, A. K., Maurice, M., Morling, F. J., Cosset, F. L. and Russell, S. J. (1998) Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood, 91: 1802-9.
34. Friedmann, T. (2003a) Gene therapy's new era: a balance of unequivocal benefit and unequivocal harm. Mol. Ther., 8: 5-7.
35. Friedmann, T. (2003b) Slide presentation of Review of Selected American Society of Gene Therapy (ASGT) Annual Meeting Sessions Related to Retroviral Vectors. NIH RAC meeting held on June 18-19 2003 Website: http://www.webconferencescom/nihoba/18-19june2003.html].
36. Gordon, E. M., Liu, P. X., Chen, Z. H., Liu, L., Whitley, M. D., Gee, C., Groshen, S., Hinton, D. R., Beart, R. W. and Hall, F. L. (2000) Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res. 60: 3343-7.
37. Goulaouic, H. and Chow, S. A. (1996) Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein. J. Virol., 70: 37-46.
38. Greco, E., Fogar, P., Basso, D., Stefani, A. L., Navaglia, F., Zambon, C. F., Mazza, S., Gallo, N., Piva, M. G., Scarpa, A., Pedrazzoli, S. and Plebani, M. (2002) Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumor effect. Pancreas, 25: e21-9.
39. Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J. L., Fraser, C. C., Cavazzana-Calvo, M. and Fischer, A. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348: 255-6.
40. Hafenrichter, D. G., Ponder, K. P., Rettinger, S. D., Kennedy, S. C., Wu, X., Saylors, R. S. and Flye, M. W. (1994) Liver-directed gene therapy: evaluation of liver specific promoter elements. J. Surg. Res., 56: 510-7.
41. Hall, F. L., Liu, L., Zhu, N. L., Stapfer, M., Anderson, W. F., Beart, R. W. and Gordon, E. M. (2000) Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum. Gene Ther., 11: 983-93.
42. Hatzoglou, M., Lamers, W., Bosch, F., Wynshaw-Boris, A., Clapp, D. W. and Hanson, R. W. (1990) Hepatic gene transfer in animals using retroviruses containing the promoter from the gene for phosphoenolpyruvate carboxykinase. J. Biol. Chem., 265: 17285-93.
43. Heneine, W., Switzer, W. M., Sandstrom, P., Brown, J., Vedapuri, S., Schable, C. A., Khan, A. S., Lerche, N. W., Schweizer, M., Neumann-Haefelin, D., Chapman, L. E. and Folks, T. M. (1998) Identification of a human population infected with simian foamy viruses. Nat. Med., 4: 403-7.
44. Hunter, E. and Swanstrom, R. (1990) Retrovirus envelope glycoproteins. Curr. Top. Microbiol. Immunol., 157: 187-253.
45. Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., Fujita, M., Ishii, N., Tamaoki, T., Shiku, H. and Nagataki, S. (1995) Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res., 55: 3105-9.
46. Ido, A., Uto, H., Moriuchi, A., Nagata, K., Onaga, Y., Onaga, M., Hori, T., Hirono, S., Hayashi, K., Tamaoki, T. and Tsubouchi, H. (2001) Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res., 61: 3016-21.
47. Ismail, S. I., Kingsman, S. M., Kingsman, A. J. and Uden, M. (2000) Split-intron retroviral vectors: enhanced expression with improved safety. J. Virol., 74: 2365-71.
48. Ismail, S. I., Rohll, J. B., Kingsman, S. M., Kingsman, A. J. and Uden, M. (2001) Use of intron-disrupted polyadenylation sites to enhance expression and safety of retroviral vectors. J. Virol., 75: 199-204.
49. Jamieson, A. C., Miller, J. C. and Pabo, C. O. (2003) Drug discovery with engineered zinc-finger proteins. Nat. Rev. Drug Discov. 2: 361-8.
50. Kaiser, J. (2003) Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science, 299: 495.
51. Katz, R. A., Merkel, G. and Skalka, A. M. (1996) Targeting of retroviral integrase by fusion to a heterologous DNA binding domain: in vitro activities and incorporation of a fusion protein into viral particles. Virology, 217: 178-90.
52. Katz, R. A. and Skalka, A. M. (1994) The retroviral enzymes. Annu. Rev. Biochem., 63: 133-73.
53. Kellum, R. and Schedl, P. (1991) A position-effect assay for boundaries of higher order chromosomal domains. Cell, 64: 941-50.
54. Khare, P. D., Shao-Xi, L., Kuroki, M., Hirose, Y., Arakawa, F., Nakamura, K. and Tomita, Y. (2001) Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Res., 61 370-5.
55. Kim, J. S. and Pabo, C. O. (1998) Getting a handhold on DNA: design of poly-zinc finger proteins with femtomolar dissociation constants. Proc. Natl. Acad. Sci. USA, 95: 2812-7.
56. Knipper, R., Kuehlcke, K., Schiedlmeier, B., Hildinger, M., Lindemann, C., Schitz, A. J., Fauser, A. A., Fruehauf, S., Zeller, W. J., Ostertag, W., Eckert, H. G. and Baum, C. (2001) Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. Gene Ther., 8: 239-46.
57. Kohn, D. B., Sadelain, M. and Glorioso, J. C. (2003) Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer, 3: 477-88.
58. Kurre, P., Morris, J., Thomasson, B., Kohn, D. B. and Kiem, H. P. (2003) Scaffold attachment region-containing retrovirus vectors improve long-term proviral expression after transplantation of GFP-modified CD34+ baboon repopulating cells. Blood, 102: 3117-9.
59. Kwaks, T. H., Barnett P., Hemrika, W., Siersma, T., Sewalt, R. G., Satijn, D. P., Brons, J. F., Van Blokland, R., Kwakman, P., Kruckeberg, A. L., Kelder, A. and Otte, A. P. (2003) Identification of anti-repressor elements that confer high and stable protein production in mammalian cells. Nat. Biotechnol., 21: 553-8.
60. Labrador, M. and Corces, V. G. (2002) Setting the boundaries of chromatin domains and nuclear organization. Cell, 111: 151-4.
61. Lee, C. W., Martinek, V., Usas, A., Musgrave, D., Pickvance, E. A., Robbins, P., Moreland, M. S., Fu, F. H. and Huard, J. (2002) Muscle-based gene therapy and tissue engineering for treatment of growth plate injuries. J. Pediatr. Orthop., 22: 565-72.
62. Lee, K. H., Song, S. U., Hwang, T. S., Yi, Y., Oh, I. S., Lee, J. Y., Choi, K. B., Choi, M. S. and Kim, S. J. (2001) Regeneration of hyaline cartilage by cell-mediated gene therapy using transforming growth factor beta I-producing fibroblasts. Hum. Gene Ther., 12 1805-13.
63. Lieberman, J. R., Ghivizzani, S. C. and Evans, C. H. (2002) Gene transfer approaches to the healing of bone and cartilage. Mol. Ther., 6: 141-7.
64. Lin, A. H., Kasahara, N., Wu, W., Stripecke, R., Empig, C. L., Anderson, W. F. and Cannon, P. M. (2001) Receptor-specific targeting mediated by the coexpression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein. Hum. Gene Ther., 12: 323-32.
65. Lorimer, I. A. and Lavictoire, S. J. (2000) Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe. J. Immunol. Methods, 237: 147-57.
66. Lotti, F. and Mavilio, F. (2003) The choice of a suitable lentivirus vector: transcriptional targeting. Methods Mol. Biol., 229: 17-27.
67. Martin, F., Chowdhury, S., Neil, S., Phillipps, N. and Collins, M. K. (2002) Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. Mol. Ther., 5: 269-74.
68. Maurice, M., Mazur, S., Bullough, F. J., Salvetti, A., Collins, M. K., Russell, S. J. and Cosset F. L. (1999) Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins. Blood, 94: 401-10.
69. Mavria, G., Jager, U. and Porter, C. D. (2000) Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Ther., 7: 368-76.
70. Mergia, A., Chari, S., Kolson, D. L., Goodenow, M. M. and Ciccarone, T. (2001) The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs. Virology, 280 243-52.
71. Modlich, U., Pugh, C. W. and Bicknell, R. (2000) Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther., 7: 896-902.
72. Namciu, S. J., Blochlinger, K. B. and Fournier, R. E. (1998) Human matrix attachment regions insulate transgene expression from chromosomal position effects in Drosophila melanogaster. Mol. Cell Biol., 18: 2382-91.
73. Nemunaitis, J., Fong, T., Robbins, J. M., Edelman, G., Edwards, W., Paulson, R. S., Bruce, J., Ognoskie, N., Wynne, D., Pike, M., Kowal, K., Merritt, J. and Ando, D. (1999) Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther. 6: 322-30.
74. Nilson, B. H., Morling, F. J., Cosset, F. L. and Russell, S. J. (1996) Targeting of retroviral vectors through protease-substrate interactions. Gene Ther., 3: 280-6.
75. Nussenbaum, B., Rutherford, R. B., Teknos, T. N., Dornfeld, K. J. and Krebsbach, P. H. (2003) Ex vivo gene therapy for skeletal regeneration in cranial defects compromised by postoperative radiotherapy. Hum. Gene Ther., 14: 1107-15.
76. Orchard, P. J., Blazar, B. R., Burger, S., Levine, B., Basso, L., Nelson, D. M., Gordon, K., McIvor, R. S., Wagner, J. E. and Miller, J. S. (2002) Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Hum. Gene Ther., 13: 979-88.
77. Overbaugh, J., Miller, A. D. and Eiden, M. V. (2001) Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol. Mol. Biol. Rev., 65: 371-89, table of contents.
78. Ozturk-Winder, F., Renner, M., Klein, D., Muller, M., Salmons, B. and Gunzburg, W. H. (2002) The murine whey acidic protein promoter directs expression to human mammary tumors after retroviral transduction. Cancer Gene Ther., 9: 421-31.
79. Palmer, G., Pascher, A., Gouze, E., Gouze, J. N., Betz, O., Spector, M., Robbins, P. D., Evans, C. H. and Ghivizzani, S. C. (2002) Development of gene-based therapies for cartilage repair. Crit. Rev. Eukaryot. Gene Expr., 12: 259-73.
80. Pandya, S., Boris-Lawrie, K., Leung, N. J., Akkina, R. and Planelles, V. (2001) Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system. Hum. Gene Ther., 12: 847-57.
81. Pannell, D. and Ellis, J. (2001) Silencing of gene expression: implications for design of retrovirus vectors. Rev. Med. Virol., 11: 205-17.
82. Peng, K. W., Morling, F. J., Cosset, F. L., Murphy, G. and Russell, S. J. (1997) A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum. Gene Ther., 8 729-38.
83. Peng, K. W., Vile, R., Cosset, F. L. and Russell, S. (1999) Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther., 6: 1552-7.
84. Poeschla, E. M., Wong-Staal, F. and Looney, D. J. (1998) Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med., 4: 354-7.
85. Ramezani, A. and Hawley, R. G. (2003) Human immunodeficiency virus type 1-based vectors for gene delivery to human hematopoietic stem cells. Methods Mol. Med., 76: 467-92.
86. Rivella, S., Callegari, J. A., May, C., Tan, C. W. and Sadelain, M. (2000) The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol. 74: 4679-87.
87. Robbins, P. D., Evans, C. H. and Chernajovsky, Y. (2003) Gene therapy for arthritis. Gene Ther., 10: 902-11.
88. Romano, G., Reiss, K., Tu, X., Peruzzi, F., Belletti, B., Wang, J. Y., Zanocco-Marani, T. and Baserga, R. (2001) Efficient in vitro and in vivo gene regulation of a retrovirally delivered pro-apoptotic factor under the control of the Drosophila HSP70 promoter. Gene Ther., 8: 600-7.
89. Royer-Pokora, B., Loos, U. and Ludwig, W. D. (1991) TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene, 6: 1887-93.
90. Schneider, R. M., Medvedovska, Y., Hartl, I., Voelker, B., Chadwick, M. P., Russell, S. J., Cichutek, K. and Buchholz, C. J. (2003) Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Ther., 10: 1370-80.
91. Schroder, A. R., Shinn, P., Chen, H., Berry, C., Ecker, J. R. and Bushman, F. (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 110: 521-9.
92. Schweizer, M., Falcone, V., Gange, J., Turek, R. and Neumann-Haefelin, D. (1997) Simian foamy virus isolated from an accidentally infected human individual. J. Virol., 71: 4821-4.
93. Sclimenti, C. R., Thyagarajan, B. and Calos, M. P. (2001) Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucleic Acids Res., 29: 5044-51.
94. Somia, N. and Verma, I. M. (2000) Gene therapy: trials and tribulations. Nat. Rev. Genet., 1: 91-9.
95. Somia, N. V., Miyoshi, H., Schmitt, M. J. and Verma, I. M. (2000) Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotyping. J. Virol., 74: 4420-4.
96. Sparmann, G., Walther, W., Gunzburg, W. H., Uckert, W. and Salmons, B. (1994) Conditional expression of human TNF-alpha: a system for inducible cytotoxicity. Int. J. Cancer, 59: 103-7.
97. Stover, M. L., Wang, C. K., McKinstry, M. B., Kalajzic, I., Gronowicz, G., Clark, S. H., Rowe, D. W. and Lichtler, A. C. (2001) Bone-directed expression of Colla1 promoter-driven self-inactivating retroviral vector in bone marrow cells and transgenic mice. Mol. Ther. 3: 543-50.
98. Sun, F. L. and Elgin, S. C. (1999) Putting boundaries on silence. Cell, 99: 459-62.
99. Tanaka, A. S., Tanaka, M. and Komuro, K. (1998) A highly efficient method for the site-specific integration of transfected plasmids into the genome of mammalian cells using purified retroviral integrase. Gene, 216: 67-76.
100. Thomas, C. E., Ehrhardt, A. and Kay, M. A. (2003) Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet., 4: 346-58.
101. Ting, Y. T., Wilson, C. A., Farrell, K. B., Chaudry, G. J. and Eiden, M. V. (1998) Simian sarcoma-associated virus fails to infect Chinese hamster cells despite the presence of functional gibbon ape leukemia virus receptors. J. Virol., 72: 9453-8.
102. Uch, R., Gerolami, R., Faivre, J., Hardwigsen, J., Mathieu, S., Mannoni, P. and Bagnis, C. (2003) Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences. Cancer Gene Ther., 10: 689-95.
103. Vile, R., Miller, N., Chernajovsky, Y. and Hart, I. (1994) A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther., 1: 307-16.
104. Walther, W., Stein, U., Fichtner, I., Alexander, M., Shoemaker, R. H. and Schlag, P. M. (2000) Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors. Cancer Gene Ther., 7: 893-900.
105. Walther, W., Wendt, J. and Stein, U. (1997) Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther., 4: 544-52.
106. Wei, S. Q., Mizuuchi, K. and Craigie, R. (1997) A large nucleoprotein assembly at the ends of the viral DNA mediates retroviral DNA integration. EMBO J., 16: 7511-20.
107. White, J. M. (1992) Membrane fusion. Science, 258 917-24.
108. Wu, X., Li, Y., Crise, B. and Burgess, S. M. (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science, 300: 1749-51.
109. Xu, K., Ma, H., McCown, T. J., Verma, I. M. and Kafri, T. (2001) Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther., 3: 97-104.
110. Yamada, Y., Warren, A. J., Dobson, C., Forster, A., Pannell, R. and Rabbitts, T. H. (1998) The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc. Natl. Acad. Sci. USA 95: 3890-5.
111. Yannaki, E., Tubb, J., Aker, M., Stamatoyannopoulos, G. and Emery, D. W. (2002) Topological constraints governing the use of the chicken HS4 chromatin insulator in oncoretrovirus vectors. Mol. Ther. 5: 589-98.
112. Yu, S. F., von Ruden, T., Kantoff, P. W., Garber, C., Seiberg, M., Ruther, U., Anderson, W. F., Wagner, E. F. and Gilboa, E. (1986) Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA, 83 3194-8.
113. Yu, S. S., Kim, J. M. and Kim, S. (2000) High efficiency retroviral vectors that contain no viral coding sequences. Gene Ther. 7: 797-804.
114. Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L. and Trono, D. (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol., 72: 9873-80.